Revance Products: Complete Guide for Aesthetic Practices

Key Takeaways

• Revance is a rapidly growing aesthetics and skincare company formed through the 2025 merger of Revance Therapeutics and Crown Laboratories, creating a comprehensive portfolio spanning neuromodulators, dermal fillers, and medical devices.
• DAXXIFY is the first and only FDA-approved peptide-formulated neuromodulator, receiving approval in September 2022 for glabellar lines with a median duration of six months—twice as long as traditional neurotoxins.
• The RHA Collection represents the only FDA-approved hyaluronic acid fillers specifically designed for dynamic facial wrinkles and folds, manufactured by TEOXANE in Switzerland using Preserved Network Technology.
• Wholesale pricing typically runs $600–$800 per 100-unit vial for DAXXIFY and $300–$400 per syringe for RHA fillers, though exact costs vary based on volume agreements and supplier relationships.
• Portrait Care offers tiered pricing, bulk discounts, and streamlined ordering to help clinics source Revance Aesthetics products profitably.

About Revance

When patients ask about longer-lasting alternatives to BOTOX or natural-looking fillers, they're increasingly referring to Revance products. This aesthetics innovator has disrupted the injectable market with first-of-its-kind technologies.

Revance Therapeutics was founded in 1999 as Essentia Biosystems, a Silicon Valley-based biotechnology company focused on developing innovative neuromodulators. The company spent over two decades in research and development, ultimately achieving FDA approval for DAXXIFY in September 2022—the first true innovation in neuromodulator formulation in over 30 years. In January 2020, Revance secured exclusive U.S. distribution rights for TEOXANE's RHA Collection of dermal fillers, positioning the company as a full-service provider of facial injectables.

In August 2024, Crown Laboratories announced a merger agreement to acquire Revance Therapeutics for approximately $924 million. The acquisition closed in February 2025, creating a comprehensive aesthetics and skincare company. Following the merger, the combined company operates under the Revance name, led by CEO Nadeem Moiz (who succeeded founder Jeff Bedard in October 2025). The company now operates from corporate offices in Dallas, Texas, with distribution spanning over 60 countries.

Revance at a Glance

• Parent company: Revance (formerly Crown Laboratories, Inc.)
• Merger completed: February 2025
• Corporate headquarters: Dallas, Texas
• Primary aesthetic products: DAXXIFY, RHA Collection, SkinPen
• Market position: Innovation leader in long-lasting neuromodulators and dynamic fillers
• Regulatory status: FDA-approved injectables and FDA-cleared devices
• Geographic reach: 60+ countries

Who Owns Revance?

Following the completion of the February 2025 merger, Revance is owned by Crown Laboratories, which Hildred Capital Management, a healthcare-focused private equity firm, backs. The merger united Crown's established skincare portfolio (including PanOxyl, Blue Lizard, and StriVectin) with Revance Therapeutics' innovative injectable products,

Is Revance a Good Company?

Is Revance a good company? Based on market performance and product innovation, Revance has established itself as a serious competitor in the aesthetics space. DAXXIFY generated $84 million in 2023 revenue, with Q2 2024 showing 27% year-over-year growth. The company maintains distribution spanning 60 countries and relationships with thousands of medical professionals. For practitioners seeking differentiated products with clinical advantages over legacy brands, Revance offers a compelling portfolio backed by extensive clinical research.

Revance Aesthetics Product List

Revance's product lineup spans three primary categories, each addressing specific treatment needs and patient demographics. Understanding these categories helps you build a service menu that maximizes both patient outcomes and practice profitability.

1. Injectable Aesthetics: Neuromodulators

DAXXIFY represents Revance's flagship neuromodulator—the first and only peptide-formulated, long-lasting neurotoxin on the market. FDA-approved for both cosmetic (glabellar lines) and therapeutic (cervical dystonia) indications, DAXXIFY addresses the duration limitation that has long been the greatest unmet need in the neuromodulator category.

2. Injectable Aesthetics: Dermal Fillers

The RHA Collection, manufactured by TEOXANE SA in Switzerland and exclusively distributed in the United States by Revance, offers the only FDA-approved hyaluronic acid fillers for dynamic facial wrinkles and folds. The collection includes RHA 2, RHA 3, RHA 4, and RHA Redensity, each engineered for specific treatment applications using Preserved Network Technology.

3. Medical Devices

SkinPen Precision, a Crown Aesthetics product now part of the Revance portfolio, is the first FDA-cleared microneedling device. With indications for facial acne scars and neck wrinkles, SkinPen provides practices with a complementary regenerative treatment that pairs well with injectable protocols.

4. Professional Skincare

The combined Revance portfolio includes established skincare brands such as PanOxyl (acne treatment), Blue Lizard (sunscreen), StriVectin (anti-aging), and BIOJUVE (skin microbiome technology). For clinics looking to extend patient relationships beyond treatment appointments, professional skincare can generate recurring revenue and build long-term loyalty.

What Does Revance Make? Top Products Overview

1. DAXXIFY (DaxibotulinumtoxinA-lanm)

DAXXIFY is Revance's flagship neuromodulator and represents the most significant innovation in the category since BOTOX received FDA approval. It received FDA approval for cosmetic use (glabellar lines) in September 2022, followed by approval for cervical dystonia in August 2023.

• Typical wholesale cost: $600–$800 per 100-unit vial (varies by volume and supplier agreements)
• Clinical use: 40 units for glabellar lines (compared to 20 units for BOTOX)
• Duration: Median of 6 months, with some patients maintaining results at 9 months
• Market position: First peptide-formulated, long-lasting neuromodulator

What is the new product replacing Botox? While DAXXIFY isn't replacing BOTOX, it offers a significant advancement for patients and practices seeking longer-lasting results. The SAKURA Phase 3 clinical program—the largest ever conducted for glabellar lines—enrolled more than 2,700 patients who received approximately 4,200 treatments. Results showed 74% of patients achieved a two-grade or greater improvement at week 4, and 98% achieved none or mild wrinkle severity per investigator assessment.

DAXXIFY's Peptide Exchange Technology (PXT) stabilizes the neurotoxin without human serum albumin or animal-based components, potentially reducing immunogenicity concerns. The product is manufactured exclusively in the United States, which provides supply chain advantages for domestic practices. For practitioners evaluating Revance Aesthetics products, DAXXIFY's extended duration can reduce patient visit frequency while maintaining consistent results.

2. RHA Collection (Resilient Hyaluronic Acid)

The RHA Collection represents the only FDA-approved hyaluronic acid fillers specifically indicated for dynamic facial wrinkles and folds. What brand makes RHA fillers? TEOXANE SA, a Swiss laboratory founded in 2003, manufactures the RHA Collection using patented Preserved Network Technology, and Revance holds exclusive U.S. distribution rights.

RHA 2 is designed for moderate facial wrinkles and folds. Its softer formulation makes it ideal for accordion cheek lines, moderate lip lines, and lip augmentation in patients seeking subtle enhancement.

RHA 3 offers balanced firmness for moderate to severe wrinkles. It excels at lip enhancement, marionette lines, and oral commissures, providing the right amount of structural support while maintaining natural movement.

RHA 4 provides the firmest formulation for moderate to severe facial wrinkles and folds. Its higher G' value makes it suitable for deeper nasolabial folds, smile lines, and areas requiring significant structural support.

RHA Redensity is the newest addition, designed explicitly for superficial dynamic perioral wrinkles (lipstick lines). Its ultra-thin formulation allows for precise treatment of delicate areas without adding bulk.

• Typical wholesale cost: Varies by formulation and volume (retail $650–$1,000 per syringe)
• Clinical use: 1 mL per syringe, treatment volumes vary by indication
• Duration: Up to 15 months for facial wrinkles and folds
• Market position: Only FDA-approved HA fillers for dynamic facial lines

What are Revance's key products? The Revance filler portfolio differentiates itself through Preserved Network Technology (PNT), which uses a gentle, heatless manufacturing process that preserves the natural structure of hyaluronic acid. This creates gels with the highest stretch and dynamic strength of all HA fillers on the market, allowing them to move naturally with facial expressions rather than appearing stiff or unnatural.

For clinics comparing Revance filler options against competitors like Restylane or JUVÉDERM, the RHA Collection offers a unique positioning: fillers engineered explicitly for the dynamic zones of the face where natural movement matters most.

3. SkinPen Precision

SkinPen Precision, now part of the Revance portfolio through Crown Aesthetics, holds the distinction of being the first FDA-cleared microneedling device. It received initial clearance for facial acne scars in 2018 and expanded clearance for neck wrinkles in 2021.

• Technology: Controlled micro-injuries stimulate natural wound healing and collagen production
• Treatment areas: Facial acne scars, neck wrinkles
• Session duration: Approximately 30 minutes
• Results timeline: Improvement visible after three treatment sessions spaced 30 days apart

The SkinPen Precision Elite, launched in December 2024, features a better user experience with easy-to-install RFID cartridges and active retraction technology (ActiSine). The device comes with a lifetime warranty, making it an attractive investment for practices seeking reliable regenerative technology.

SkinPen treatments pair exceptionally well with injectable protocols, providing a complementary approach to facial rejuvenation. The device works for all Fitzpatrick skin types and generates substantial ROI for practices seeking to expand their service menu beyond injectables.

4. Professional Skincare Portfolio

The combined Revance portfolio includes established skincare brands for both professional and consumer markets:

PanOxyl offers benzoyl peroxide acne treatments available both by prescription and over-the-counter, providing practices with an accessible entry point for acne-prone patients.

Blue Lizard delivers dermatologist-recommended mineral sunscreens, essential for post-procedure care and ongoing skin health maintenance.

StriVectin offers medical-grade anti-aging skincare powered by peptide technology, complementing injectable treatments for comprehensive facial rejuvenation.

BIOJUVE represents an innovative approach to skin health through microbiome technology, offering differentiated skincare options for practices seeking cutting-edge products.

For aesthetic practices, recommending professional skincare extends patient relationships beyond treatment appointments and positions your clinic as a comprehensive skin health resource.

Wholesale vs. Retail Pricing

Understanding the spread between what you pay and what patients pay determines whether Revance Aesthetics products work for your clinic's economics.

What Clinics Pay (Wholesale)

• DAXXIFY: $600–$800 per 100-unit vial
• RHA Collection: Wholesale varies by formulation and volume agreements
• SkinPen treatment kits: Varies by distributor; device costs $3,000–$6,000 with ongoing cartridge expenses

What Patients Pay (Typical Retail)

• DAXXIFY: $12–$20 per unit (40-unit treatment typically $480–$800)
• RHA Collection: $650–$1,000 per syringe
• SkinPen: $300–$500 per treatment session

The economics of DAXXIFY require careful consideration. While the per-unit cost may appear higher than traditional neurotoxins, the extended duration (6 months vs. 3–4 months) means patients need fewer annual treatments. A patient who receives 2 DAXXIFY treatments per year at $600 each ($1,200 annually) may actually spend less than a patient receiving 4 BOTOX treatments at $400 each ($1,600 annually).

For RHA fillers, the pricing aligns with premium HA products like Restylane and JUVÉDERM. The differentiation comes from clinical positioning—these are the only fillers specifically indicated for dynamic facial areas, which can support premium pricing for patients who prioritize natural movement.

That's why your supplier relationship—and the pricing tiers you can access—directly impacts whether Revance products make sense for your practice. Expert consultations help patients understand the value proposition of these differentiated products.

Are Revance Aesthetics Products FDA-Approved?

Running an aesthetic clinic means meeting strict regulatory standards. Here's what you need to know when stocking Revance Aesthetics products.

FDA Approval Status

All primary Revance aesthetic products carry FDA approval or clearance:

DAXXIFY received FDA approval for cosmetic use (glabellar lines) in September 2022 based on the SAKURA Phase 3 clinical program. A second approval for cervical dystonia followed in August 2023, expanding DAXXIFY's therapeutic applications.

RHA Collection products are FDA-approved for dermal augmentation across their formulations. RHA 2, RHA 3, and RHA 4 are approved for moderate to severe dynamic facial lines, wrinkles, and folds. RHA Redensity received approval for perioral rhytids (lip lines), and RHA 3 carries an additional indication for lip augmentation. These represent the only HA fillers specifically approved for dynamic facial applications.

SkinPen Precision received FDA 510(k) clearance (K202243) for improving the appearance of facial acne scars and neck wrinkles. The device maintains both FDA clearance and CE marking, making it available for global distribution.

Practitioner Licensing Requirements

Licensing requirements vary by state and treatment type. Generally:

Injectables (DAXXIFY, RHA Collection) require administration by licensed physicians, nurse practitioners, or physician assistants under physician supervision. Some states allow licensed RNs to inject under specific protocols, but medical director oversight remains essential.

SkinPen treatments may be performed by trained aestheticians under physician supervision in many states, though regulations vary. Verify your state's specific requirements before adding microneedling services.

Skincare products are not subject to license restrictions on recommendations or sales, making them an accessible revenue source for all staff members.

Storage and Handling Requirements

DAXXIFY requires refrigeration at 2–8°C and should be reconstituted immediately before use. Unlike BOTOX, DAXXIFY uses Peptide Exchange Technology that eliminates reconstitution variability, though proper storage remains critical. RHA products should be stored at room temperature (up to 25°C) and protected from freezing. Products must remain in original packaging with lot numbers tracked for traceability.

Pros, Cons, and Best Fit

Advantages of Revance Aesthetics Products

• First-in-class neuromodulator technology positions DAXXIFY as the only peptide-formulated, long-lasting option on the market. The 6-month median duration addresses the greatest unmet need in the neurotoxin category.
• Unique filler placement with the RHA Collection provides the only FDA-approved fillers specifically indicated for dynamic facial wrinkles—a significant differentiator for patients who prioritize natural movement.
• Clean formulation story appeals to increasingly ingredient-conscious patients. DAXXIFY contains no human serum albumin or animal-based components, while RHA fillers use a gentle manufacturing process that preserves natural HA structure.
• U.S. manufacturing for DAXXIFY provides supply chain security and insulation from international tariffs or disruptions—an increasingly important consideration for practice planning.
• Comprehensive skincare integration through the merged company allows practices to source injectables, devices, and professional skincare from a single supplier, simplifying vendor management.

Disadvantages of Revance Aesthetics Products

• Lower brand recognition than BOTOX or JUVÉDERM means some patients specifically request legacy brands. Converting these patients requires education about clinical advantages and differentiated results.
• Higher per-unit complexity for DAXXIFY can confuse patients when comparing prices across practices. The 2:1 unit conversion (40 units DAXXIFY vs. 20 units BOTOX for glabellar lines) requires clear communication.
• Limited indication breadth compared to BOTOX, which has dozens of therapeutic approvals. DAXXIFY currently holds only two indications (glabellar lines and cervical dystonia).
• Premium pricing structure may not align with practices focused on value-conscious patient demographics or high-volume, low-margin business models.

Best Fit for Revance Aesthetics Products

Revance products work well for:

• Practices seeking differentiated positioning against competitors offering only legacy brands
• Clinics serving patients who prioritize longer-lasting results and fewer appointments
• Growing practices that want to establish expertise in next-generation technologies
• Practitioners seeking products with unique clinical data and first-mover positioning
• Multi-service clinics looking to pair advanced injectables with regenerative device treatments

Revance products may not be ideal for:

• Practices where patients exclusively demand BOTOX or JUVÉDERM by name
• Clinics focused on the lowest possible acquisition costs, regardless of clinical differentiation
• Startups with limited training bandwidth for new product protocols
• Markets with highly price-sensitive patient demographics

Alternatives to Revance Aesthetics Products

Understanding your options helps you build a product mix that balances innovation, margin requirements, and patient preferences.

Neuromodulator Alternatives

• BOTOX Cosmetic (onabotulinumtoxinA) remains the most recognized neurotoxin brand globally. Higher brand awareness supports premium pricing, but a 3–4 month duration requires more frequent treatments than DAXXIFY.
• Dysport (abobotulinumtoxinA) offers a faster onset (2–3 days vs. 5–7 days) and broader diffusion that some injectors prefer for larger treatment zones. Pricing typically runs $3–$4 per unit at wholesale.
• Xeomin (incobotulinumtoxinA) provides a "naked" neurotoxin, devoid of accessory proteins, appealing to patients concerned about antibody formation. Duration similar to BOTOX at 3–4 months.
• Jeuveau (prabotulinumtoxinA) entered the market as a "modern" BOTOX alternative with competitive pricing. Duration and performance similar to legacy neurotoxins.

Filler Alternatives

• Restylane Collection (Galderma) offers the world's most diverse range of HA fillers, backed by over 27 years of clinical data. Strong reputation, but not indicated explicitly for dynamic facial applications.
• JUVÉDERM Collection (Allergan/AbbVie) uses VYCROSS technology for smooth consistency and longer duration in some formulations. Voluma lasts up to 2 years for cheek augmentation.
• Radiesse (Merz) uses calcium hydroxyapatite for immediate volume plus biostimulation. Longer duration (12+ months) but not reversible like HA fillers.

Why Practitioners Choose Alternatives

Brand recognition drives many decisions—BOTOX and JUVÉDERM command category-defining positioning that simplifies patient acquisition. Some patients respond better to specific formulations, making diversification clinically valuable. Exclusive agreements with manufacturers can provide preferential pricing for committed practices. Biostimulators offer another differentiation strategy worth considering.

How to Choose the Right Products

Step 1: Define Your Clinical Niche

Start by identifying your target patient demographic and treatment focus. Are you a full-service aesthetic clinic or a specialist focused on specific treatments? Do you serve luxury clientele seeking the latest innovations or price-sensitive patients prioritizing value? What's your practitioner expertise—are you comfortable training on new technologies? Your answers shape which products make sense for your practice, whether you're launching a new clinic or refining an existing one.

Step 2: Evaluate Your Practice Economics

Calculate realistic margins for each product, including wholesale cost vs. retail pricing in your specific market, patient volume needed to access favorable pricing tiers, storage and handling requirements, and staff training investments.

The DAXXIFY calculation differs from traditional neurotoxins. If DAXXIFY wholesale runs $700 per 100-unit vial and you use 40 units per treatment at $15 per unit ($600 retail), your gross margin is $320 per patient. With a 6-month duration, annual revenue per patient is approximately $1,200 with $640 in gross profit. Compare this to traditional neurotoxins, where patients return 3–4 times annually.

Step 3: Assess Market Demand in Your Geography

Research competitor positioning and patient preferences in your area. Markets with established BOTOX dominance may require significant education to convert patients to DAXXIFY. Urban areas with affluent demographics and early adopter tendencies may embrace innovation more readily. Check local competitor websites to understand whether anyone is already offering Revance products—being first provides differentiation, but being second requires a different positioning strategy.

Step 4: Consider Portfolio Breadth vs. Focus

Choose Revance Aesthetics products if you want a first-mover advantage with innovative technologies, your market responds to longevity and "clean" formulation messaging, you value unique clinical data and differentiated positioning, or you're building a premium practice focused on clinical excellence over price competition.

Choose alternatives if patients in your market specifically demand BOTOX or JUVÉDERM by name, you prefer working in a single-manufacturer ecosystem like Allergan/AbbVie or Galderma, or simplified training on familiar products better serves your team.

Step 5: Test Before Committing

Order sample quantities of products you're considering and train staff on application and patient education. Track patient satisfaction, retention, and repeat booking rates. Monitor wholesale pricing stability over 3–6 months before making significant inventory commitments. Revance's 6-month duration for DAXXIFY means you'll need fewer follow-up data points to assess patient satisfaction.

Step 6: Build Your Product Mix

Most successful practices use a hybrid approach: one or two neurotoxins covering both traditional and long-lasting options, one primary filler brand with alternatives for specific indications, complementary device offerings, such as microneedling, for regenerative protocols, and professional skincare to extend patient relationships and increase lifetime value.

Buy Revance Aesthetics Products with Portrait Care

Your purchasing strategy determines whether innovative products generate margins at the innovation level or squeeze your profitability. Assess your practice's volume needs and growth trajectory—this determines your pricing tier and negotiating leverage.

As you grow, revisit your supplier relationships quarterly. Review purchasing patterns, evaluate product performance against patient demand, and renegotiate terms as you move into higher-volume brackets. The difference between good and excellent supplier relationships often shows up directly on your bottom line.

If you're ready to stock Revance's innovative portfolio, Portrait Care provides the infrastructure, pricing advantages, and operational support needed to do it profitably.

Portrait Care offers:

• Tiered pricing based on monthly purchase volume
• Bulk discounts for clinics ordering large quantities
• Standing order programs for predictable products like monthly DAXXIFY shipments
• Online ordering portal for convenience and real-time inventory tracking
• Expert guidance on building a product mix that serves your patients and your margins

Whether you're launching a new aesthetics clinic or expanding an established practice, Portrait Care can help you source Revance Aesthetics products at competitive wholesale pricing while providing the operational support you need to succeed.

Contact Portrait Care to get started.